← The patent line

Amino Acids; Calcium Chloride; Dextrose; Magnesium Sulfate; Potassium Chloride; Sodium Acetate; Sodium Glycerophosphate; Soybean Oil

Sold as KABIVEN IN PLASTIC CONTAINER, PERIKABIVEN IN PLASTIC CONTAINER · given by intravenous

Five to ten years until it comes off patent
9.7 yr
Until anyone may copy it
Protection runs to 2036-05-03
8
Trials running now
34720 registered in total
In routine use
Furthest stage reached
already in routine clinical use
3
Organisations running trials
lead sponsors on record
01

Who owns it, and until when

Fresenius Kabi Usa Llc
Approval holder
the only company permitted to sell it today
2036-05
Last patent expires
latest patent filed against this product
none listed
FDA exclusivity ends
a separate protection granted at approval

Whichever date falls later is when other manufacturers may apply to sell copies. Price typically falls steeply within a year of that point, and with it any company's ability to recover the cost of new research on the molecule. That is when it becomes a candidate for the ledger on the first tab.

02

What it is being tested for

DiabetesDiabetes Mellitus, Type 2Type 2 Diabetes Mellitus
03

Who is paying for the research

Bristol-Myers Squibb
Company
3
Eli Lilly and Company
Company
3
National Cancer Institute (NCI)
US government
2

Who funds the trials matters after protection lapses. Company-funded work usually stops once exclusivity ends; university, hospital and government-funded work does not, and is the research most likely to continue on this molecule afterwards.

04

The trials themselves

NCT07125664Phase 22025 · 36 people · not yet recruiting
Intravenous Alpha-1 Antitrypsin for Hospital

Expiry dates are what the patent holder has filed; litigation, paediatric extensions and settlements routinely move them, so read these as the earliest plausible date rather than a schedule. Not medical advice.

← Back to the patent line